Despite this growing body of preclinical data supporting a role for GSK3β in diabetes, most clinical trials using GSK3β inhibitors study neurological diseases such as Alzheimer's Disease and Progressive Supranuclear Palsy [97,98]. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.